Polyphor AG (POLN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Polyphor AG (POLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7610
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Polyphor AG (Polyphor) is a clinical stage biopharmaceutical company that discovers and develops antibiotics and other specialty pharma products for severe or life-threatening diseases. The company offers hematopoietic stem cells for multiple myeloma patients, Pseudomonas infections and protease inhibitors for chronic obstructive pulmonary disease, alpha-1-antitrypsin deficiency, cystic fibrosis and lung diseases, among others. It develops various technology platforms which include MacroFinder and PEMfinder that are used to discover the potent and selective modulators of protein-protein interactions. It also develops proprietary macrocycle technology platform for pharma companies. Polyphor is headquartered in Allschwil, Switzerland.

Polyphor AG (POLN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Polyphor AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Polyphor AG, Medical Devices Deals, 2012 to YTD 2018 9
Polyphor AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Polyphor AG, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Polyphor Raises USD7 Million in Financing 11
Partnerships 12
Polyphor Enters into Licensing Agreement with PARI Pharma 12
Polyphor Enters into Research Agreement with Taisho Pharma 13
Licensing Agreements 14
Santhera Pharma Enters into Licensing Agreement with Polyphor 14
Polyphor Extends Licensing Agreement with Boehringer Ingelheim 15
Gilead Sciences Enters Into Licensing Agreement With Polyphor 16
Equity Offering 17
Polyphor Raises USD167.4 Million in IPO of Shares 17
Polyphor Raises USD10 Million in Private Financing 18
Polyphor AG – Key Competitors 19
Polyphor AG – Key Employees 20
Polyphor AG – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Sep 06, 2018: Polyphor reports financial results for the first half 2018 22
Corporate Communications 24
May 24, 2017: Kalina Scott appointed new CFO of Polyphor 24
Government and Public Interest 25
Jan 23, 2018: Polyphor: Global No. 2 in the 2018 Antimicrobial Resistance Benchmark published by the Access to Medicine Foundation 25
Product News 26
07/18/2017: Polyphor achieves ahead of schedule first milestone from Wellcome Trust for the development of novel antibiotics against Gram-negative multidrug – resistant pathogens 26
02/09/2017: Polyphor Receives CHF 2.3 Million Award from Wellcome Trust to Accelerate the Development of a Novel Antibiotic Drug Class 27
Other Significant Developments 28
Apr 13, 2018: Polyphor successfully completes Wellcome Trust collaboration for development of novel antibiotics against multi-drug resistant Gram-negative pathogens 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Polyphor AG, Pharmaceuticals & Healthcare, Key Facts 2
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Polyphor AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Polyphor AG, Deals By Therapy Area, 2012 to YTD 2018 8
Polyphor AG, Medical Devices Deals, 2012 to YTD 2018 9
Polyphor AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Polyphor Raises USD7 Million in Financing 11
Polyphor Enters into Licensing Agreement with PARI Pharma 12
Polyphor Enters into Research Agreement with Taisho Pharma 13
Santhera Pharma Enters into Licensing Agreement with Polyphor 14
Polyphor Extends Licensing Agreement with Boehringer Ingelheim 15
Gilead Sciences Enters Into Licensing Agreement With Polyphor 16
Polyphor Raises USD167.4 Million in IPO of Shares 17
Polyphor Raises USD10 Million in Private Financing 18
Polyphor AG, Key Competitors 19
Polyphor AG, Key Employees 20

List of Figures
Polyphor AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Polyphor AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Polyphor AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Polyphor AG, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Polyphor AG (POLN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pacific & Orient Berhad:企業の戦略・SWOT・財務分析
    Pacific & Orient Berhad - Strategy, SWOT and Corporate Finance Report Summary Pacific & Orient Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Swelect Energy Systems Ltd (SWELECTES):電力:M&Aディール及び事業提携情報
    Summary Swelect Energy Systems Ltd (SESL), formerly Numeric Power Systems Ltd is an energy company that manufactures and markets renewable energy products and iron and steel products. The company’s renewable energy products include solar pv modules, solar inverter, solar water pump and energy effici …
  • iPass Inc. (IPAS):企業の財務・戦略的SWOT分析
    iPass Inc. (IPAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Athena Investments AS (ATHENA):企業の財務・戦略的SWOT分析
    Athena Investments AS (ATHENA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Enel Generacion Peru SAA (EDEGELC1):企業の財務・戦略的SWOT分析
    Summary Enel Generacion Peru SAA (Enel Generacion) a subsidiary of Enel Americas SA, is a power generation company. It offers transmission and distribution of electricity. The company generates electricity through thermal and hydroelectric sources. It also carries out hydroelectric plant generation …
  • Italgas SpA-石油・ガス分野:企業M&A・提携分析
    Summary Italgas SpA (Italgas), a subsidiary of Snam SpA, is an oilfield service company that offers transportation and dispatching of natural gas, liquefied natural gas regasification, and storage and distribution of natural gas. The company's activities include rhino-analytical tests; instrumental …
  • eResearchTechnology Inc:医療機器:M&Aディール及び事業提携情報
    Summary eResearchTechnology Inc (ERT) is a global data and technology company that provides electronic data collection solutions for clinical development programmes. Its services assist companies in achieving their drug development and healthcare objectives. ERT uses its technology, processes and sc …
  • Tricida Inc (TCDA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company. The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases. Its lead drug candidate TRC101, is under clinical dev …
  • Sosei Group Corp (4565):製薬・医療:M&Aディール及び事業提携情報
    Summary Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhe …
  • Biomedical Structures LLC-医療機器分野:企業M&A・提携分析
    Summary Biomedical Structures LLC (BMS) is a medical device company that designs, develops and manufactures medical textiles. The company manufacturers devices and structures including knitted, braided, woven, non-woven, custom structures, and materials. It offers consulting services such as design …
  • Cyan Limited:企業の戦略・SWOT・財務情報
    Cyan Limited - Strategy, SWOT and Corporate Finance Report Summary Cyan Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Australian Securities & Investments Commission:企業の戦略的SWOT分析
    Australian Securities & Investments Commission - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • RIKEN-製薬・医療分野:企業M&A・提携分析
    Summary RIKEN is a research organization, which carries out research in basic and applied sciences. Its research system consists of strategic research centers, research infrastructure centers, chief scientist system, etc. and a cluster for industry partnerships. Its centers, laboratories and researc …
  • Zanders GmbH:企業の戦略的SWOT分析
    Zanders GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Modern Water plc (MWG):企業の財務・戦略的SWOT分析
    Summary Modern Water Plc (Modern Water) is a clean technology company that develops and supplies water monitoring systems. The company owns, installs and operates membrane technologies, develops and supplies systems for water monitoring. Its membrane process division utilizes forward osmosis technol …
  • Australian Pharmaceutical Industries Ltd (API):企業の財務・戦略的SWOT分析
    Australian Pharmaceutical Industries Ltd (API) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • LifeAssays AB (LIFE B):医療機器:M&Aディール及び事業提携情報
    Summary LifeAssays AB (LifeAssays) is a medical device company that develops, manufactures and markets in-vitro diagnostic and veterinary care products. The company offers point-of-care diagnostic testing systems. It provides product portfolio such as lifeassays human system and lifeassays veterinar …
  • OncoMed Pharmaceuticals Inc (OMED):企業の財務・戦略的SWOT分析
    Summary OncoMed Pharmaceuticals Inc (OncoMed) is a clinical-stage biopharmaceutical company focused on discovery and development of novel immuno-oncology (IO) therapeutics for the treatment of cancers. Its pipeline product candidates include navicixizumab, rosmantuzumab, Gitrl-FC Trimer, and anti-TI …
  • POSCO:企業のM&A・事業提携・投資動向
    POSCO - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's POSCO Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisin …
  • B3 S.A.
    B3 S.A. - Strategy, SWOT and Corporate Finance Report Summary B3 S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆